Skip to content

WSA growth impacted by macro weakness in the third quarter of FY 2024/25

26 Aug 2025

Press release

Lynge, Denmark – August 26, 2025 – WSA, a leading pure-play hearing healthcare group, today announced results for the third quarter of the financial year 2024/25 (April 1, 2025 – June 30, 2025) showing organic revenue growth of -4%. Outlook for FY 2024/25 is revised: Organic growth of around 0% (previously 3-6%). EBITDA margin is expected around the lower end of the guidance of 1-2%-pts increase vs. FY2023/24.

Jan Mäkelä, CEO of WSA, said:

Macroeconomic weakness led to soft market conditions in the third quarter with consumers cancelling or postponing hearing care treatment. This resulted in a negative organic growth of 4% in the quarter compared to a very strong quarter last year of 12% organic growth, which was supported by the launch of Signia IX. Despite the market weakness, we saw strong growth in our online business in the U.S. We remain committed to helping many more people to regain the joy of hearing while delivering long-term profitable growth through innovation and disciplined cost control. This month, we are excited to announce the expansion of our Signia Integrated Xperience portfolio with two groundbreaking innovations. Due to continued market weakness in the fourth quarter, we are revising our outlook for the full financial year 2024/25.

Highlights Q3 2024/2025 (Q3 last financial year in brackets)

  • WSA delivered organic revenue growth of -4% (12%) to EUR 621 million due to market softness across key markets and US managed care negatively impacted by health care plans scaling-back their benefit plans.
  • EBITDA before special items[1] was EUR 106 million corresponding to an EBITDA margin of 17.1% (17.9%) impacted by the negative topline development. The negative effect was partly offset by tight cost control.
  • WSA continues to invest in innovation. In August, we announced the launch of Signia Insio Charge&Go CIC IX, the world’s first rechargeable, custom-made completely-in-canal (CIC) hearing aid with directional microphone technology with up to five times the speech enhancement in noise compared to other single-microphone CIC hearing aids.[2]
  • WSA also announced Signia Motion Charge&Go IX, a full lineup of rechargeable BTE hearing aids for all levels of hearing enhancement, including the longest battery runtime of any rechargeable superpower device, offering up to 61 hours of runtime, bringing the power of the IX Platform to all.

Highlights 9M 2024/2025 (9M last financial year in brackets)

  • Revenue for the first nine months of the financial year 2024/25 was EUR 1,958 million, reflecting 0% (11%) organic growth up against a high comparative base in the same period last year and impacted by the volatile macroenvironment.
  • EBITDA before special items[3] was EUR 337 million corresponding to an EBITDA margin of 17.2 % (16.3%).
  • Outlook for FY 2024/25 is revised: Organic revenue growth of around 0% (previously 3-6%). EBITDA margin is expected around the lower end of the guidance of 1-2%-pts increase vs. FY2023/24.ext

###

About WSA
WSA is a leading global pure-play hearing healthcare group, pioneering innovative technologies for over 140 years, helping millions of people with hearing loss regain the joy of hearing, engage in meaningful conversations, and participate fully in society. WSA operates in over 130 markets and employs more than 12,500 people across our hearing aid portfolio, which includes Widex and Signia, and a global network of hearing care professionals and consumer-facing businesses. WSA is privately owned by the Tøpholm and Westermann families, the Lundbeck Foundation, EQT and ATHOS KG. As a global leader, our ambition is to unlock human potential by making wonderful sound part of everyone’s life. Learn more at www.wsa.com

 

[1] Measured as EBITDA before special items and net of R&D Capex.

[2] Jensen, N. S., Samra, B., Hain, J., & Branda, E. (2025). Binaural OneMic Directionality 2.0 delivers 5 times the speech enhancement in noise versus key competitors. Signia White Paper.

[3] Measured as EBITDA before special items and net of R&D Capex.